丁苯酞联合胰激肽原酶辅助治疗脑梗死的临床效果

Clinical effect of butylphthalide combined with pancreatic kininogenase in adjuvant treatment of cerebral infarction

目的观察丁苯酞联合胰激肽原酶辅助治疗脑梗死的临床效果。方法选择2018年10月-2019年12月湖南省益阳市人民医院收治的脑梗死患者72例,采用随机数字表法分为观察组和对照组各36例。在常规治疗的基础上,对照组患者应用胰激肽原酶治疗,观察组患者在对照组治疗的基础上联合丁苯酞治疗。比较2组患者治疗前后神经功能缺损情况、日常生活能力、临床疗效及不良反应。结果治疗后,2组患者NIHSS评分均低于治疗前,Barthel指数均高于治疗前,且观察组患者变化幅度大于对照组(P <0.01);观察组患者临床治疗总有效率为66.67%,高于对照组的41.67%(χ^(2)=4.532,P <0.05);观察组患者不良反应总发生率为5.56%,对照组患者不良反应总发生率为8.33%,2组患者不良反应总发生率比较差异无统计学意义(χ^(2)=0.215,P=0.643)。结论丁苯酞联合胰激肽原酶辅助治疗脑梗死患者的临床疗效显著,同时可改善患者的神经功能缺损与生活质量,且临床使用安全性高,值得临床推广应用。

Objective To observe the clinical effect of butylphthalide combined with pancreatic kininogenase in adjuvant treatment of cerebral infarction. Methods From October 2018 to December 2019,72 patients with cerebral infarction admitted to the People’s Hospital of Yiyang City,Hunan Province were selected and divided into observation group and control group with 36 cases each by random number table. On the basis of conventional treatment,patients in the control group were treated with pancreatic kininogenase,and patients in the observation group were treated with butylphthalide in addition to the treatment in the control group. The neurological deficits,activities of daily living,clinical efficacy and adverse reactions of the two groups before and after treatment were compared. Results After treatment,the NIHSS scores of the two groups were lower than those before treatment,and the Barthel index was higher than that before treatment,and the changes in the observation group were greater than those in the control group( P < 0. 01);The total effective rate of clinical treatment in the observation group was 66. 67%,which was higher than 41. 67% in the control group( χ^(2)= 4. 532,P < 0. 05);The total incidence of adverse reactions in the observation group was 5. 56%,and the total incidence of adverse reactions in the control group was8. 33%. There was no significant difference in the total incidence of adverse reactions between the two groups( χ^(2)= 0. 215,P = 0. 643). Conclusion Butylphthalide combined with pancreatic kininogenase has a significant clinical effect in adjuvant treatment of patients with cerebral infarction. At the same time,it can improve patients’ neurological deficits and quality of life,and has high clinical safety,which is worthy of clinical application.